Resectable disease
Treatment of Resectable Mucosal Melanoma
When mucosal melanoma is resectable, curative-intent treatment is possible. Incorporating systemic therapy around the time of surgery — before and after — has become central to improving outcomes in this setting.
Clinical Scenario
This protocol addresses patients with resectable mucosal melanoma. The key premise is that neoadjuvant and adjuvant therapies can improve outcomes in resectable disease when combined with surgery.
Treatment Approach
Management involves neoadjuvant combination therapy prior to surgery, followed by surgical resection and an adjuvant treatment course — with the specific regimen depending on tumour location within the mucosa.
Full regimen options, sequencing, and dosing are in the complete protocol →
References
- Neoadjuvant and adjuvant therapies can improve outcomes in resectable MM.
- In a single-center, open-label phase II clinical trial, patients with resectable MM received four cycles of toripalimab and axitinib as neoadjuvant therapy, followed by surgery and adjuvant toripalimab.
- In another study, 15 patients received two cycles of neoadjuvant therapy with lenvatinib and pembrolizumab, followed by surgery and 15 cycles of adjuvant pembrolizumab.
- Besides, many cases using ipilimumab/nivolumab as neoadjuvant therapy reported achieving long-lasting remission.
DOI: 10.1200/EDBK-25-473858
View source ↗